Study Finds Child-Centered Disclosure Improves Well-Being in Pediatric ALL - Oncology Nurse Advisor Semi-structured interviews with children with ALL revealed a desire for clinicians to tell them about their disease directly in age-appropriate language.

Timely, developmentally tailored diagnostic disclosure may reduce anxiety and strengthen coping among school-aged children with acute #lymphoblasticLeukemia.

https://bit.ly/3PlZRt5

#ALL #leusm

Lowering Induction Daunorubicin Dosage Does Not Reduce Efficacy in Pediatric B-Cell ALL - Oncology Nurse Advisor Researchers sought to determine whether reducing the induction daunorubicin dose among pediatric patients with low-risk B-cell ALL would compromise efficacy.

Reducing the induction daunorubicin dose among pediatric patients with low-risk B-cell acute #lymphoblasticLeukemia appears to reduce toxicity without compromising efficacy. Published in @ascopost.bsky.social and @hematologyadvisor.bsky.social.

https://bit.ly/4cmwfVQ

#leusm #ALL

Treating Pediatric ALL Can Lead to Household Income Loss, Financial Hardship - Hematology Advisor Study researchers aimed to describe the cumulative incidence of financial toxicity among families with a child being treated for ALL, as well as the sociodemographic factors associated with the development of financial toxicity.

Many families with children being treated for acute #lymphoblasticLeukemia face household material hardship and/or income loss. Presented at #ASH25, covered by @cancertherapyadv.bsky.social.

https://bit.ly/3L7JaQj

#ALL #leusm

Apixaban Safe, Effective as VTE Prophylaxis in Obese Pediatric Patients With ALL/LL - Oncology Nurse Advisor Researchers sought to determine whether apixaban would be a safe and effective prophylactic treatment for VTE in obese pediatric patients with ALL/LL

Apixaban is safe and effective as VTE prophylaxis in obese pediatric patients with acute #lymphoblasticLeukemia and lymphoma. Published in @bloodjournals.hematology.org and @hematologyadvisor.bsky.social.

https://bit.ly/4rZ8N6J

#leusm #lymsm

Many families with children being treated for acute #lymphoblasticLeukemia face household material hardship and/or income loss. Presented at #ASH25 by Daniel Zheng, MD from Children's Hospital of Philadelphia.

https://bit.ly/3YgIR8N

#leusm #ALL

GINMEMA ALL2820: Targeted Immunotherapy Regimen May Represent New First-Line SOC in Ph+ ALL Targeted immunotherapy significantly improved responses and prolonged survival in newly-diagnosed Ph+ ALL compared with chemotherapy.

A chemotherapy-free treatment approach with targeted immunotherapy significantly improved responses and prolonged survival in newly-diagnosed Ph+ acute #lymphoblasticLeukemia. Presented at #ASH25 .

https://bit.ly/48GDpkz

#leusm

Significant Barriers Exist in Accessing Initial Oncology Care Among Young Adults with ALL Researchers determined AYAs with ALL trying to schedule oncology appointments face logistical burdens when accessing initial oncology care.

A secret shopper study in which researchers posed as AYAs with acute #lymphoblasticLeukemia trying to schedule an #oncology appointment has found that this population faces significant logistical burdens when accessing initial oncology care.

https://bit.ly/3XBFHfA

#leusm #ASCO25

Apixaban Safe, Effective as VTE Prophylaxis in Obese Pediatric Patients With ALL/LL Researchers determined apixaban is safe and effective as VTE prophylaxis in obese pediatric patients with ALL/LL.

Apixaban is safe and effective as VTE prophylaxis in #obese pediatric patients with acute #lymphoblasticLeukemia and lymphoma. Published in @bloodjournal.bsky.social.

https://bit.ly/4ap9bow

#leusm

Significant Barriers Exist in Accessing Initial Oncology Care Among Young Adults with ALL Researchers determined AYAs with ALL trying to schedule oncology appointments face logistical burdens when accessing initial oncology care.

A secret shopper study in which researchers posed as AYAs with acute #lymphoblasticLeukemia trying to schedule an #oncology appointment has found that this population faces significant logistical burdens when accessing initial oncology care. From #ASCO25.

https://bit.ly/4ib5gh0

#leusm #lymsm

Psychopathology Is Common Among Pediatric Patients With ALL Patients with high-risk and intermediate-risk ALL were significantly more likely to have a psychopathology than those with standard-risk ALL.

An increased prevalence of psychiatric comorbidities may be common in pediatric patients with acute #lymphoblasticleukemia. From @rarediseaseadvisor.bsky.social.

bit.ly/45mYuzL

#leusm #lymsm

Predicting Methotrexate-Related Neurotoxicity Risk in Patients With ALL - Oncology Nurse Advisor Study identifies the characteristics that predict risk for methotrexate-related neurotoxicity in young patients being treated for ALL.

Researchers developed a new risk prediction model for methotrexate-related neurotoxicity in young patients being treated for acute #lymphoblasticLeukemia.

bit.ly/4fk04Gg

#leusm

Acute Lymphoblastic Leukemia Research Grant Dr. Maureen O’Brien will study the use of inotuzumab ozogamicin.

Dr. Maureen O'Brien was awarded the R50 Clinical Scientist Award by the National Cancer Institute to lead multiple clinical trials testing the antibody drug inotuzumab ozogamicin for #LymphoblasticLeukemia treatment.

Personalized Algorithm May Aid in HDMTX Infusion in Pediatric ALL - Oncology Nurse Advisor Researchers sought to determine whether a real-time personalized algorithm may help to effectively plan HDMTX infusion among pediatric patients with ALL.

A real-time personalized algorithm may help to effectively plan HDMTX infusion among pediatric patients with acute #lymphoblasticLeukemia in non-optimal clinical settings. Published in @ascocancer.bsky.social journal JCO Global Oncology and @hematologyadvisor.bsky.social.

bit.ly/3ZoFmy6

#leusm

Targeting Socioeconomic Vulnerability Mitigates Cost Burden During ALL Induction - Oncology Nurse Advisor Parents of children with ALL experience a high financial burden during the early phase of their child’s treatment trajectory.

Early in therapy for pediatric acute #lymphoblasticLeukemia, substantial financial burden and distress are already entrenched, underscoring the need for systematic screening and intervention from diagnosis.

bit.ly/4khDakk

#leusm

Personalized Algorithm May Aid in HDMTX Infusion in Pediatric ALL Researchers determined a real-time personalized algorithm may help to effectively plan HDMTX infusion among pediatric patients with ALL in non-optimal clinical settings.

A real-time personalized algorithm may help to effectively plan HDMTX infusion among pediatric patients with acute #lymphoblasticLeukemia in non-optimal clinical settings. Published in @ascocancer.bsky.social JCO Global Oncology.

bit.ly/3GESnNy